Neurotensin receptor binding and neurotensin-induced growth signaling in prostate cancer PC3 cells are sensitive to metabolic stress

Regulatory Peptides

Volumn 141, Issue 1-3, 2007, Pages 140-153

  Carraway, Robert E ^a   Hassan, Sazzad ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Cancer cell growth; G protein coupled receptor; Growth signaling; Metabolic stress; Metabolism; Neurotensin; Receptor binding

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ADENOSINE TRIPHOSPHATE; ANTIMYCIN A1; CARBONYL CYANIDE CHLOROPHENYLHYDRAZONE; CIGLITAZONE; DEOXYGLUCOSE; DICOUMAROL; G PROTEIN COUPLED RECEPTOR; GROWTH FACTOR RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INOSITOL PHOSPHATE; MYXOTHIAZOL; NEUROTENSIN; NEUROTENSIN RECEPTOR; OLIGOMYCIN; ROTENONE; TROGLITAZONE;

ARTICLE; CELL LEVEL; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DNA SYNTHESIS; ENZYME ACTIVATION; GLYCOLYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; METABOLIC STRESS; MITOCHONDRION; MITOGENESIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN METABOLISM; RECEPTOR BINDING;

ADENOSINE TRIPHOSPHATE; AMINOIMIDAZOLE CARBOXAMIDE; BLOTTING, WESTERN; CELL LINE, TUMOR; DNA; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; INOSITOL PHOSPHATES; KINETICS; MALE; MULTIENZYME COMPLEXES; NEUROTENSIN; PROSTATIC NEOPLASMS; PROTEIN BINDING; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, NEUROTENSIN; RIBONUCLEOTIDES; SIGNAL TRANSDUCTION; STRESS;

EID: 33947595787     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2006.12.027     Document Type: Article

References (69)

1. Fryer L.G., Parbu-Patel A., and Carling D. The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem 277 28 (2002) 25226-25232
2. Hardie D.G., Scott J.W., Pan D.A., and Hudson E.R. Management of cellular energy by the AMP-activated protein kinase system. FEBS Lett 546 1 (2003) 113-120
3. Swinnen J.V., Beckers A., Brusselmans K., Organe S., Segers J., Timmermans L., Vanderhoydonc F., Deboel L., Derua R., Waelkens E., De Schrijver E., Van de Sande T., Noel A., Foufelle F., and Verhoeven G. Mimicry of a cellular low energy status blocks tumor cell anabolism and suppresses the malignant phenotype. Cancer Res 65 6 (2005) 2441-2448
4. Rattan R., Giri S., Singh A.K., and Singh I. 5-Aminoimidazole-4-carboxamide-1-beta-d-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J Biol Chem 280 47 (2005) 39582-39593
5. Hassan S., and Carraway R.E. Involvement of arachidonic acid metabolism and EGF receptor in neurotensin-induced prostate cancer PC3 cell growth. Regul Pept 133 1-3 (2006) 105-114
6. Hassan S., Dobner P.R., and Carraway R.E. Involvement of MAP-kinase, PI3-kinase and EGF-receptor in the stimulatory effect of neurotensin on DNA synthesis in PC3 cells. Regul Pept 120 1-3 (2004) 155-166
7. Vincent J.P., Mazella J., and Kitabgi P. Neurotensin and neurotensin receptors. Trends Pharmacol Sci 20 7 (1999) 302-309
8. Wood J.G., Hoang H.D., Bussjaeger L.J., and Solomon T.E. Neurotensin stimulates growth of small intestine in rats. Am J Physiol 255 6 Pt 1 (1988) G813-G817
9. Hasegawa K., Kar S., and Carr B.I. Stimulation of hepatocyte DNA synthesis by neurotensin. J Cell Physiol 158 2 (1994) 215-222
10. Evers B.M. Neurotensin and growth of normal and neoplastic tissues. Peptides 27 10 (2006) 2424-2433
11. Reubi J.C., Waser B., Schaer J.C., and Laissue J.A. Neurotensin receptors in human neoplasms: high incidence in Ewing's sarcomas. Int J Cancer 82 2 (1999) 213-218
12. Elek J., Pinzon W., Park K.H., and Narayanan R. Relevant genomics of neurotensin receptor in cancer. Anticancer Res 20 1A (2000) 53-58
13. Moody T.W., Chiles J., Casibang M., Moody E., Chan D., and Davis T.P. SR48692 is a neurotensin receptor antagonist which inhibits the growth of small cell lung cancer cells. Peptides 22 1 (2001) 109-115
14. Davis T.P., Burgess H.S., Crowell S., Moody T.W., Culling-Berglund A., and Liu R.H. Beta-endorphin and neurotensin stimulate in vitro clonal growth of human SCLC cells. Eur J Pharmacol 161 2-3 (1989) 283-285
15. Ishizuka J., Townsend Jr. C.M., and Thompson J.C. Neurotensin regulates growth of human pancreatic cancer. Ann Surg 217 5 (1993) 439-445 [discussion 446]
16. Guha S., Lunn J.A., Santiskulvong C., and Rozengurt E. Neurotensin stimulates protein kinase C-dependent mitogenic signaling in human pancreatic carcinoma cell line PANC-1. Cancer Res 63 10 (2003) 2379-2387
17. Poinot-Chazel C., Portier M., Bouaboula M., Vita N., Pecceu F., Gully D., Monroe J.G., Maffrand J.P., Le Fur G., and Casellas P. Activation of mitogen-activated protein kinase couples neurotensin receptor stimulation to induction of the primary response gene Krox-24. Biochem J 320 Pt 1 (1996) 145-151
18. Maoret J.J., Anini Y., Rouyer-Fessard C., Gully D., and Laburthe M. Neurotensin and a non-peptide neurotensin receptor antagonist control human colon cancer cell growth in cell culture and in cells xenografted into nude mice. Int J Cancer 80 3 (1999) 448-454
19. Sehgal I., Powers S., Huntley B., Powis G., Pittelkow M., and Maihle N.J. Neurotensin is an autocrine trophic factor stimulated by androgen withdrawal in human prostate cancer. Proc Natl Acad Sci U S A 91 11 (1994) 4673-4677
20. Hursting S.D., Thornquist M., and Henderson M.M. Types of dietary fat and the incidence of cancer at five sites. Prev Med 19 3 (1990) 242-253
21. Barber D.L., Cacace A.M., Raucci D.T., and Ganz M.B. Fatty acids stereospecifically stimulate neurotensin release and increase [Ca2+]i in enteric endocrine cells. Am J Physiol 261 3 Pt 1 (1991) G497-G503
22. Rosell S., and Rokaeus A. The effect of ingestion of amino acids, glucose and fat on circulating neurotensin-like immunoreactivity (NTLI) in man. Acta Physiol Scand 107 3 (1979) 263-267
23. Carraway R., and Plona A.M. Involvement of neurotensin in cancer growth: evidence, mechanisms and development of diagnostic tools. Peptides 27 10 (2006) 2445-2460
24. Landis S.H., Murray T., Bolden S., and Wingo P.A. Cancer statistics 1999. CA Cancer J Clin 49 1 (1999) 8-31 [1]
25. Higuchi M., Kudo T., Suzuki S., Evans T.T., Sasaki R., Wada Y., Shirakawa T., Sawyer J.R., and Gotoh A. Mitochondrial DNA determines androgen dependence in prostate cancer cell lines. Oncogene 25 10 (2006) 1437-1445
26. Vias M., Burtt G., Culig Z., Veerakumarasivam A., Neal D.E., and Mills I.G. A role for neurotensin in bicalutamide resistant prostate cancer cells. Prostate (2006)
27. Seethalakshmi L., Mitra S.P., Dobner P.R., Menon M., and Carraway R.E. Neurotensin receptor expression in prostate cancer cell line and growth effect of NT at physiological concentrations. Prostate 31 3 (1997) 183-192
28. Warburg O. On the origin of cancer cells. Science 123 3191 (1956) 309-314
29. Xu R.H., Pelicano H., Zhou Y., Carew J.S., Feng L., Bhalla K.N., Keating M.J., and Huang P. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 65 2 (2005) 613-621
30. Buzzai M., Bauer D.E., Jones R.G., Deberardinis R.J., Hatzivassiliou G., Elstrom R.L., and Thompson C.B. The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid beta-oxidation. Oncogene 24 26 (2005) 4165-4173
31. Izyumov D.S., Avetisyan A.V., Pletjushkina O.Y., Sakharov D.V., Wirtz K.W., Chernyak B.V., and Skulachev V.P. Wages of fear: transient threefold decrease in intracellular ATP level imposes apoptosis. Biochim Biophys Acta 1658 1-2 (2004) 141-147
32. Ko Y.H., Smith B.L., Wang Y., Pomper M.G., Rini D.A., Torbenson M.S., Hullihen J., and Pedersen P.L. Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun 324 1 (2004) 269-275
33. Carling D. The AMP-activated protein kinase cascade-a unifying system for energy control. Trends Biochem Sci 29 1 (2004) 18-24
34. Hardie D.G., and Carling D. The AMP-activated protein kinase-fuel gauge of the mammalian cell?. Eur J Biochem 246 2 (1997) 259-273
35. Kemp B.E., Stapleton D., Campbell D.J., Chen Z.P., Murthy S., Walter M., Gupta A., Adams J.J., Katsis F., van Denderen B., Jennings I.G., Iseli T., Michell B.J., and Witters L.A. AMP-activated protein kinase, super metabolic regulator. Biochem Soc Trans 31 Pt 1 (2003) 162-168
36. Stefanelli C., Stanic I., Bonavita F., Flamigni F., Pignatti C., Guarnieri C., and Caldarera C.M. Inhibition of glucocorticoid-induced apoptosis with 5-aminoimidazole-4-carboxamide ribonucleoside, a cell-permeable activator of AMP-activated protein kinase. Biochem Biophys Res Commun 243 3 (1998) 821-826
37. Blazquez C., Geelen M.J., Velasco G., and Guzman M. The AMP-activated protein kinase prevents ceramide synthesis de novo and apoptosis in astrocytes. FEBS Lett 489 2-3 (2001) 149-153
38. Xiang X., Saha A.K., Wen R., Ruderman N.B., and Luo Z. AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem Biophys Res Commun 321 1 (2004) 161-167
39. Wu M., and Ho S.M. PMP24, a gene identified by MSRF, undergoes DNA hypermethylation-associated gene silencing during cancer progression in an LNCaP model. Oncogene 23 1 (2004) 250-259
40. Brown J. Effects of 2-deoxyglucose on carbohydrate metabolism: review of the literature and studies in the rat. Metabolism 11 (1962) 1098-1112
41. Singer T.P. Mitochondrial electron-transport inhibitors. Methods Enzymol 55 (1979) 454-462
42. Brunmair B., Staniek K., Gras F., Scharf N., Althaym A., Clara R., Roden M., Gnaiger E., Nohl H., Waldhausl W., and Furnsinn C. Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions?. Diabetes 53 4 (2004) 1052-1059
43. Shiau C.W., Yang C.C., Kulp S.K., Chen K.F., Chen C.S., and Huang J.W. Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma. Cancer Res 65 4 (2005) 1561-1569
44. Watanabe J., Nishiyama H., Matsui Y., Ito M., Kawanishi H., Kamoto T., and Ogawa O. Dicoumarol potentiates cisplatin-induced apoptosis mediated by c-Jun N-terminal kinase in p53 wild-type urogenital cancer cell lines. Oncogene 25 17 (2006) 2500-2508
45. McLennan H.R., and Degli Esposti M. The contribution of mitochondrial respiratory complexes to the production of reactive oxygen species. J Bioenerg Biomembr 32 2 (2000) 153-162
46. Boveris A. Determination of the production of superoxide radicals and hydrogen peroxide in mitochondria. Methods Enzymol 105 (1984) 429-435
47. Tirosh O., Aronis A., and Melendez J.A. Mitochondrial state 3 to 4 respiration transition during Fas-mediated apoptosis controls cellular redox balance and rate of cell death. Biochem Pharmacol 66 8 (2003) 1331-1334
48. Carraway R.E., Mitra S.P., and Honeyman T.W. Effects of GTP analogs and metal ions on the binding of neurotensin to porcine brain membranes. Peptides 14 1 (1993) 37-45
49. Carraway R.E., Gui X., and Cochrane D.E. Ca2+ channel blockers enhance neurotensin (NT) binding and inhibit NT-induced inositol phosphate formation in prostate cancer PC3 cells. J Pharmacol Exp Ther 307 2 (2003) 640-650
50. Beaudet A., Mazella J., Nouel D., Chabry J., Castel M.N., Laduron P., Kitabgi P., and Faure M.P. Internalization and intracellular mobilization of neurotensin in neuronal cells. Biochem Pharmacol 47 1 (1994) 43-52
51. Bozou J.C., Rochet N., Magnaldo I., Vincent J.P., and Kitabgi P. Neurotensin stimulates inositol trisphosphate-mediated calcium mobilization but not protein kinase C activation in HT29 cells. Involvement of a G-protein. Biochem J 264 3 (1989) 871-978
52. Carraway R.E., Hassan S., and Cochrane D.E. Polyphenolic antioxidants mimic the effects of 1,4-dihydropyridines on neurotensin receptor function in PC3 cells. J Pharmacol Exp Ther 309 1 (2004) 92-101
53. Larkin J.M., Donzell W.C., and Anderson R.G. Modulation of intracellular potassium and ATP: effects on coated pit function in fibroblasts and hepatocytes. J Cell Physiol 124 3 (1985) 372-378
54. Jing M., and Ismail-Beigi F. Role of 5′-AMP-activated protein kinase in stimulation of glucose transport in response to inhibition of oxidative phosphorylation. Am J Physiol Cell Physiol 290 2 (2006) C484-C491
55. Kudo N., Barr A.J., Barr R.L., Desai S., and Lopaschuk G.D. High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5′-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase. J Biol Chem 270 29 (1995) 17513-17520
56. Young M.E., Radda G.K., and Leighton B. Activation of glycogen phosphorylase and glycogenolysis in rat skeletal muscle by AICAR-an activator of AMP-activated protein kinase. FEBS Lett 382 1-2 (1996) 43-47
57. Li N., Wang Q., Li J., Wang X., Hellmich M.R., Rajaraman S., Greeleyd Jr. G.H., Townsend Jr. C.M., and Evers B.M. Inhibition of mitochondrial gene transcription suppresses neurotensin secretion in the human carcinoid cell line BON. Am J Physiol Gastrointest Liver Physiol 288 2 (2005) G213-G220
58. Russell III R.R., Bergeron R., Shulman G.I., and Young L.H. Translocation of myocardial GLUT-4 and increased glucose uptake through activation of AMPK by AICAR. Am J Physiol 277 2 Pt 2 (1999) H643-H649
59. Dorta D.J., Pigoso A.A., Mingatto F.E., Rodrigues T., Prado I.M., Helena A.F., Uyemura S.A., Santos A.C., and Curti C. The interaction of flavonoids with mitochondria: effects on energetic processes. Chem Biol Interact 152 2-3 (2005) 67-78
60. Triggle D.J. The 1,4-dihydropyridine nucleus: a pharmacophoric template part 1. Actions at ion channels. Mini Rev Med Chem 3 3 (2003) 215-223
61. Navarro V., Martin S., and Mazella J. Internalization-dependent regulation of HT29 cell proliferation by neurotensin. Peptides 27 10 (2006) 2502-2507
62. Bazenet C.E., Ruano A.R., Brockman J.L., and Anderson R.A. The human erythrocyte contains two forms of phosphatidylinositol-4-phosphate 5-kinase which are differentially active toward membranes. J Biol Chem 265 29 (1990) 18012-18022
63. Lichtner R.B., Menrad A., Sommer A., Klar U., and Schneider M.R. Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors. Cancer Res 61 15 (2001) 5790-5795
64. Martin S., Navarro V., Vincent J.P., and Mazella J. Neurotensin receptor-1 and-3 complex modulates the cellular signaling of neurotensin in the HT29 cell line. Gastroenterology 123 4 (2002) 1135-1143
65. Hardie D.G., Carling D., and Carlson M. The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell?. Annu Rev Biochem 67 (1998) 821-855
66. Bergeron R., Previs S.F., Cline G.W., Perret P., Russell III R.R., Young L.H., and Shulman G.I. Effect of 5-aminoimidazole-4-carboxamide-1-beta-d-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats. Diabetes 50 5 (2001) 1076-1082
67. Abbud W., Habinowski S., Zhang J.Z., Kendrew J., Elkairi F.S., Kemp B.E., Witters L.A., and Ismail-Beigi F. Stimulation of AMP-activated protein kinase (AMPK) is associated with enhancement of Glut1-mediated glucose transport. Arch Biochem Biophys 380 2 (2000) 347-352
68. Woods A., Johnstone S.R., Dickerson K., Leiper F.C., Fryer L.G., Neumann D., Schlattner U., Wallimann T., Carlson M., and Carling D. LKB1 is the uptream kinase in the AMP-activated protein kinase cascade. Curr Biol 13 22 (2003) 2004-2008
69. Gottlieb E., and Tomlinson I.P. Mitochondrial tumour suppressors: a genetic and biochemical update. Nat Rev Cancer 5 11 (2005) 857-866